You are here

Heart Failure


While 71 percent of heart patients are prescribed statins after hospitalization for heart disease, cerebrovascular disease and peripheral artery disease, just 37.4 percent retain that medication regimen a year later, researchers in Salt Lake City reported this week.

Patients who suffer brain damage after cardiac arrest could benefit from magnetic resonance (MR) imaging following their stabilization—a measure that has been shown to predict clinical outcomes through mapping brain activity, according to new research published in the American journal Radiology.

Ventricular assist devices (VADs) foster improved survival for children awaiting heart transplantation when compared to the current standard of extracorporeal membrane oxygenation (ECMO), according to a new study in the Journal of the American College of Cardiology.

African Americans are dying an average of 3.4 years before white Americans, a significant gap that’s attributable to more prevalent cardiovascular disease (CVD) and risk factors in the black population, the American Heart Association (AHA) reported in a scientific statement published Monday in Circulation.

Cardiovascular research has traditionally focused on hard clinical endpoints such as markers of disease progression, adverse events and death. But now researchers are calling for more studies that incorporate the viewpoints of patients and caregivers, both in trial design and execution and in measuring outcomes like quality of life, time off work, out-of-pocket expense and caregiver burden.


Recent Headlines

AHA releases statement on how biomarker testing could help diagnose, treat heart failure

A new scientific statement published by the American Heart Association (AHA) suggests that innovative biomarker tests for heart failure could help physicians better diagnose and treat the condition.

First patient enrolls in phase 3 heart failure study

American Regent announced on April 24 that the first patients had enrolled in a phase 3 trial evaluating an investigational heart failure medication.

FDA designates Medtronic’s recall of HVAD system controllers, DC adapters as class I recall

The FDA determined that Medtronic’s voluntary recall of its HVAD system controllers and DC adapters was a class I recall, according to a Medtronic news release on April 18.

Endotronix hires three to join its management team

Endotronix recently announced it had recently hired several executives to join its management team.

LVAD, medications can fully restore function in heart failure patients

New research from Newcastle University found the use of left ventricular assist devices (LVADs) combined with medication can fully restore heart function in patients with end stage heart failure, a major breakthrough for heart failure patients who haven’t received a transplant and are running out of options.

Advanced heart failure patients have superior outcomes with HeartMate 3 device

At six months, patients with advanced heart failure who were implanted with the HeartMate 3 left ventricular assist system were less likely to have hemocompatibility- related clinical adverse events (HRAEs) compared with those who received the HeartMate II device, according to a randomized trial.

Taller, overweight women could be at increased risk for AFib

New research from the University of Gothenburg in Sweden has suggested that bigger women, classified as those who are taller than average and are overweight, could be at a greater risk of atrial fibrillation (AFib).

Protein shown to improve cardiac function could be used for heart failure drugs

Researchers from Case Western Reserve University have found a new target for drug developers looking for ways to improve cardiac function in heart failure patients.

Subclinical hypothyroidism associated with adverse cardiac outcomes

New research from the University of Pennsylvania shows that patients with severe heart failure have higher levels of thyroid hormones, which can be responsible for causing atrial fibrillation.

Gene mutation could help develop drug to reduce heart attacks

A person's unique genetic makeup may mean greater chances of certain harmful conditions, but other times, one's genes can actually be a defense against negative health outcomes. New research from Washington University’s School of Medicine in St. Louis explores how this concept could help develop therapies intended to reduce the risk of heart attack.